|
|
|
Baseline |
4 weeks |
8 weeks |
| Number of redness Lv. 1 |
Placebo |
337.6 ± 448.8 |
391.4 ± 401.6 (53.8 ± 240.8) |
445.3 ± 390.9 (107.6 ± 332.7) |
| Delphinol® |
596.9 ± 609.3 |
480.9 ± 623.0 (−116.0 ± 413.8) |
548.8 ± 690.5 (−48.1 ± 441.2) |
|
| Area of redness Lv. 1 |
Placebo |
223.5 ± 424.5 |
315.4 ± 513.8 (91.9 ± 177.2) |
277.6 ± 363.2 (54.1 ± 192.3) |
| Delphinol® |
393.5 ± 393.6 |
289.9 ± 274.6 (−103.6 ± 274.9) |
336.6 ± 346.8 (−59.9 ± 315.9) |
|
| Number of redness Lv. 2 |
Placebo |
36.5 ± 84.4 |
65.4 ± 115.4 (28.9 ± 46.5) |
52.4 ± 73.1 (15.9 ± 51.8) |
| Delphinol® |
64.1 ± 58.9 |
35.8 ± 30.0 (−28.4 ± 34.9)* |
53.9 ± 70.1 (−10.3 ± 43.6) |
|
| Area of redness Lv.2 |
Placebo |
11.1 ± 23.6 |
21.0 ± 39.5 (9.9 ± 17.4) |
20.0 ± 36.1 (8.9 ± 16.4) |
| Delphinol® |
20.6 ± 22.2 |
11.4 ± 11.7 (−9.3 ± 13.3)* |
21.4 ± 23.8 (0.8 ± 16.5) |
|
| Number of redness Lv. 3 |
Placebo |
0.9 ± 2.1 |
2.0 ± 3.4 (1.1 ± 1.7) |
4.1 ± 7.1 (3.3 ± 5.4) |
| Delphinol® |
2.4 ± 4.2 |
1.6 ± 2.6 (−0.8 ± 1.8) |
4.5 ± 7.3 (2.1 ± 3.8) |
|
| Area of redness Lv. 3 |
Placebo |
0.1 ± 0.4 |
0.4 ± 1.1 (0.3 ± 1.2) |
0.6 ± 1.1 (0.5 ± 1.2) |
| Delphinol® |
1.6 ± 3.1 |
0.9 ± 2.1 (−0.8 ± 1.5) |
1.8 ± 3.8 (0.1 ± 1.6) |